Global mRNA Vaccine Market Expected to Decline at -4.3% CAGR Through 2034, Reaching USD 9.6 Billion

The global mRNA vaccine market was valued at USD 21.7 billion in 2023 and is expected to reach more than USD 9.6 billion by the end of 2034. The market is projected to register a negative CAGR of -4.3% from 2023 to 2034, reflecting normalization in demand following the COVID-19 pandemic. Despite the contraction, ongoing research into next-generation mRNA vaccines, diversification into non-COVID indications, and long-term innovation in vaccine platforms continue to support the market's strategic importance within the global biopharmaceutical landscape.

The mRNA vaccine market offers promising solutions for combating infectious diseases and cancers. Ongoing research and innovations are critical to enhance mRNA vaccination technologies for disease prevention and public health.

Your Key to Data-Driven Success: Explore In-Depth Data - Request Your Sample! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85998

The mRNA vaccine market is experiencing steady growth due to its capability in tackling communicable & chronic diseases, and cancer. Despite numerous challenges in combating immunological diseases and rare disease conditions, mRNA vaccines have exhibited remarkable efficacy against newly emerging viruses such as Coronavirus.

Despite the success of COVID-19 mRNA vaccines, obstacles remain, notably in terms of general availability, manufacturing efficiency, and safety. Accessibility continues to be a major challenge, particularly in nations with limited resources and infrastructure. Cold storage requirements worsen the problem, preventing delivery and administration in remote places.

Market Segmentation

The market can be segmented across various criteria, demonstrating the technology's widespread application:

By mRNA Construct Type (Product Type)

Conventional Non-Amplifying mRNA-Based Vaccines (Dominant): Held the largest market share in 2024 due to their proven track record and widespread adoption during the COVID-19 pandemic.

Self-Amplifying mRNA-Based Vaccines (saRNA) (Fastest Growth): Expected to grow rapidly as they require lower doses and potentially offer longer-lasting immune responses.

Circular mRNA (Emerging): Gaining traction for enhanced stability and reduced immunogenicity.

Therapeutic Drugs.
Others.

By Application (Industry Vertical)

Infectious Diseases (Dominant): Accounted for the major market share in 2024, driven by COVID-19 vaccines, RSV (Respiratory Syncytial Virus) vaccines (like Moderna's FDA-approved mRESVIA in 2024), and influenza vaccines.
Oncology (Fastest Growing): Personalized cancer vaccines and immunotherapies are a significant growth area, aiming to treat various cancers like melanoma, pancreatic, and lung cancer.
Autoimmune Diseases.
Rare Genetic Disorders.
Others.

By Service/Sourcing Type (CDMO Market Example)

While "Service Type" and "Sourcing Type" are more relevant to the Contract Development and Manufacturing Organization (CDMO) segment, key service areas include:

mRNA Drug Substance Manufacturing (IVT) (Dominant in CDMO): Manufacturing the core mRNA molecule.

End-to-End CDMO Services: Integrated drug development from plasmid to vial.
LNP Formulation & Encapsulation: Critical for stable delivery.

By End-User

Hospitals & Clinics (Dominant).
Biopharmaceutical & Biotechnology Companies.
Research Organizations and Academic Institutes.
Regional Analysis

North America commanded the largest market share in 2024, fueled by robust healthcare infrastructure, substantial R&D investments, and a strong presence of key market players.

Asia-Pacific is projected to be the fastest-growing regional market over the forecast period, driven by rising investments in biotechnology, supportive regulatory frameworks, and increasing public health initiatives in countries like China, Japan, and India.

Market Drivers and Challenges

Market Drivers

Technological Advancements in Delivery Systems: Innovations in Lipid Nanoparticle (LNP) delivery enhance mRNA stability, bioavailability, and cellular uptake.

Expanding Applications Beyond Vaccines: The platform is increasingly explored for therapeutics in oncology, rare diseases, and protein replacement.

Rapid Development and Scalability: The cell-free synthesis process allows for faster production and quick adaptation to emerging pathogens and variants, a key factor in pandemic preparedness.

Increased R&D Funding and Strategic Collaborations: Surging private and public investment post-COVID-19 accelerates clinical trials and commercialization.

🚧 Market Challenges

High Development and Manufacturing Costs: The complex production processes, including those for LNPs and personalized treatments, result in high financial obligations.

Cold-Chain and Stability Requirements: Stringent cold-chain logistics are still required for many existing formulations, posing distribution challenges in remote or resource-limited regions.

Immunogenicity and Safety Concerns: Potential for triggering adverse immune responses, especially for long-term or repeat dosing, remains a research focus.
Vaccine Hesitancy and Misinformation: Public skepticism and lack of awareness present a significant hurdle to widespread adoption.

Market Trends and Future Outlook

Next-Generation mRNA Technologies: A clear trend is the evolution from linear mRNA to next-generation platforms like self-amplifying mRNA (saRNA) and circular RNA (circRNA), promising lower doses and enhanced stability.

Focus on Oncology and Personalized Medicine: The fastest-growing area is the development of therapeutic cancer vaccines tailored to an individual patient's unique tumor profile. This is expected to be the next major revenue driver after infectious disease vaccines.

Combination Vaccines: Developing single-shot mRNA vaccines that protect against multiple diseases (e.g., COVID-19 and Influenza) to improve compliance and convenience.

AI and Automation: The integration of Artificial Intelligence (AI) for neoantigen selection and the use of modular, automated manufacturing platforms will streamline development and lower production costs.

Key Market Study Points

LNP Delivery is Paramount: The continued success and expansion of the market hinge on continuous improvements in the Lipid Nanoparticle (LNP) delivery system.

COVID-19 to Chronic Diseases: The revenue shift is moving away from purely pandemic-driven demand towards sustained innovation in chronic, non-communicable diseases.

Prophylactic Dominance, Therapeutic Potential: While prophylactic vaccines (prevention) currently dominate, the massive untapped potential lies in the growth of therapeutic vaccines (treatment), particularly in cancer.

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=85998<ype=S

Competitive Landscape

The market is currently dominated by a few key players who led the charge during the pandemic, but the landscape is diversifying. Competition is intense, focusing on expanding pipelines, improving delivery technology, and securing intellectual property.

Key Market Participants Include:

Pfizer Inc.
Moderna, Inc.
BioNTech SE.
CureVac.
GlaxoSmithKline (GSK).
Daiichi Sankyo.

Companies are engaging in strategic activities such as mergers and acquisitions, international collaborations, and major investments in R&D to solidify their global footprint and technological advantage.

Recent Developments

RSV Vaccine Approval (2024): Moderna's mRESVIA received FDA approval for RSV in adults aged 60 and over, marking the first FDA-approved mRNA vaccine for a non-COVID-19 disease, validating the platform for broader applications.

Universal Flu Vaccine: Research is advancing rapidly on mRNA-based universal flu vaccines designed to protect against all 20 known influenza subtypes.

New RNA Technologies: Japan's approval of ARCT-154 (Kostaive), a self-amplifying mRNA COVID-19 vaccine, in late 2024 highlights the growing regulatory acceptance of next-generation saRNA platforms.

Oncology Pipeline Progress: Major players are seeing promising late-stage clinical trial data for personalized mRNA cancer vaccines, indicating a near-term commercialization opportunity.

Explore Latest Research Reports by Transparency Market Research:

Multiomics Market - https://www.transparencymarketresearch.com/multiomics-market.html

Brain Imaging Devices Market - https://www.transparencymarketresearch.com/brain-imaging-devices-market.html

Animal Model Market - https://www.transparencymarketresearch.com/animal-model-market.html

Femoral Heads Market - https://www.transparencymarketresearch.com/femoral-heads-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.